ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 25 Oct 2024
Last Updated on 10 Feb 2025
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:
    • adults 60 years of age or older; and
    • adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

Subsidy status

Recombinant varicella zoster virus glycoprotein E 50 mcg/0.5 mL powder and suspension for suspension for injection is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.

The recombinant varicella zoster virus glycoprotein E injection should be used in line with the additional clinical criteria listed in the Annex.

Recombinant zoster vaccine for prevention of herpes zoster and post-herpetic neuralgia (Updated 10 Feb 2025) PES Recombinant zoster vaccine for preventing shingles and related nerve pain (Updated 10 Feb 2025)